HDL-cholesterol as a marker of coronary heart disease risk: The Québec cardiovascular study

Atherosclerosis

Volumn 153, Issue 2, 2000, Pages 263-272

  Després, Jean Pierre ^a,b   Lemieux, Isabelle ^a,b   Dagenais, Gilles R ^a   Cantin, Bernard ^a,b   Lamarche, Benot ^b  

^a LAVAL UNIVERSITY   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Abdominal obesity; Cholesterol HDL cholesterol ratio; Coronary heart disease; HDL cholesterol; Triglycerides

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ATHEROGENESIS; CANADA; CARDIOVASCULAR RISK; DISEASE MARKER; HUMAN; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CORONARY DISEASE; HUMANS; MIDDLE AGED;

EID: 0034496618     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(00)00603-1     Document Type: Review

References (69)

1. Coronary heart disease in seven countries
2. Epidemiology of coronary heart disease: The Framingham study
3. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
4. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study
5. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
6. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
7. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
8. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators
9. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
10. Beyond LDL cholesterol reduction
11. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial
12. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study
13. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study
14. The Tromso Heart Study: High-density lipoprotein as a protective factor against coronary heart disease: A prospective case-control study
15. HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study
16. Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: Interim report: Dyslipidemia Working Group of Health Canada
17. Joint British recommendations on prevention of coronary heart disease in clinical practice
18. Coronary heart disease: Reducing the risk. The scientific background for primary and secondary prevention of coronary heart disease
19. Plasma triglyceride as a risk factor for coronary heart disease. The epidemiologic evidence and beyond
20. Plasma triglyceride and coronary heart disease
21. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies
22. Epidemiology of triglycerides: A view from Framingham
23. Hypertriglyceridemia and its metabolic consequences as a risk factor for atherosclerotic cardiovascular disease in non-insulin-dependent diabetes mellitus
24. Triglycerides: A risk factor for coronary heart disease
25. Hypertriglyceridemia: Risks and perspectives
26. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: Studies in randomly selected normo- and hypertriglyceridaemic men
27. Hypertriglyceridemia and regulation of fibrinolytic activity
28. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a 5-year follow-up of men in the Quebec cardiovascular study
29. Atherothrombogenicity of lipoprotein(a): The debate
30. Lipoprotein (a)
31. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction
32. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women
33. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study
34. Hyperinsulinemia as an independent risk factor for ischemic heart disease
35. Banting lecture. Role of insulin resistance in human disease
36. Plasma homocysteine as a risk factor for vascular disease
37. Plasma homocysteine levels and mortality in patients with coronary artery disease
38. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension
39. Essential hypertension: Renin and aldosterone, heart attack and stroke
40. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis
41. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
42. Atherosclerosis-an inflammatory disease
43. Novel inflammatory markers of coronary risk: Theory versus practice
44. Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease
45. Triglyceride as a risk factor for coronary heart disease
46. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment
47. Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study
48. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome
49. Did grandma give you heart disease? The new battle against coronary artery disease
50. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Quebec Cardiovascular Study)
51. New lipoprotein profiles and coronary heart disease. Improving precision of risk
52. Atherosclerosis prevention for the next decade: Risk assessment beyond low density lipoprotein cholesterol
53. Metabolic heterogeneity associated with high plasma triglyceride or low HDL cholesterol levels in men
54. The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men
55. Metabolic heterogeneity underlying postprandial lipemia among men with low fasting plasma HDL-cholesterol concentrations
56. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease
57. Postprandial triglyceride response in visceral obesity in men
58. Hypofibrinolysis and the insulin resistance syndrome
59. PAI-1, obesity, insulin resistance and risk of cardiovascular events
60. Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent?
61. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects
62. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B
63. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease
64. Hyperglycemia and cardiovascular disease in type 2 diabetes
65. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM
66. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
67. HDLs and alimentary lipemia. Studies in men with previous myocardial infarction at a young age
68. Triglyceride-rich lipoproteins and atherosclerosis
69. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol